[go: up one dir, main page]

WO2002033121A3 - Test diagnostique - Google Patents

Test diagnostique Download PDF

Info

Publication number
WO2002033121A3
WO2002033121A3 PCT/GB2001/004660 GB0104660W WO0233121A3 WO 2002033121 A3 WO2002033121 A3 WO 2002033121A3 GB 0104660 W GB0104660 W GB 0104660W WO 0233121 A3 WO0233121 A3 WO 0233121A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
diagnosis
compounds
test
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2001/004660
Other languages
English (en)
Other versions
WO2002033121A2 (fr
Inventor
David Hosford
Ian James Purvis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to AU2001295752A priority Critical patent/AU2001295752A1/en
Publication of WO2002033121A2 publication Critical patent/WO2002033121A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002033121A3 publication Critical patent/WO2002033121A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de diagnostic du diabète ou de l'éventualité d'un diabète chez un individu. Ce procédé consiste à typer dans un échantillon provenant de l'individu (i) la zone de gène de récepteur d'insuline ou (ii) la protéine de récepteur d'insuline de l'individu et à déterminer ainsi si l'individu est atteint de diabète ou susceptible de l'être.
PCT/GB2001/004660 2000-10-19 2001-10-19 Test diagnostique Ceased WO2002033121A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001295752A AU2001295752A1 (en) 2000-10-19 2001-10-19 Test for the diagnosis of diabetes and compounds for the treatment thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0025678.4A GB0025678D0 (en) 2000-10-19 2000-10-19 Diagnostic test
GB0025678.4 2000-10-19

Publications (2)

Publication Number Publication Date
WO2002033121A2 WO2002033121A2 (fr) 2002-04-25
WO2002033121A3 true WO2002033121A3 (fr) 2003-10-16

Family

ID=9901640

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/004660 Ceased WO2002033121A2 (fr) 2000-10-19 2001-10-19 Test diagnostique

Country Status (3)

Country Link
AU (1) AU2001295752A1 (fr)
GB (1) GB0025678D0 (fr)
WO (1) WO2002033121A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028540A2 (fr) * 1999-10-19 2001-04-26 Glaxo Group Limited Therapie de la douleur cephalique
WO2001028539A2 (fr) * 1999-10-19 2001-04-26 Glaxo Group Limited Agent pour le traitement de la douleur cephalique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028540A2 (fr) * 1999-10-19 2001-04-26 Glaxo Group Limited Therapie de la douleur cephalique
WO2001028539A2 (fr) * 1999-10-19 2001-04-26 Glaxo Group Limited Agent pour le traitement de la douleur cephalique

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
KAN MASAHARU ET AL: "Frequency of mutations of insulin receptor gene in Japanese patients with NIDDM.", DIABETES, vol. 44, no. 9, 1995, pages 1081 - 1086, XP009006871, ISSN: 0012-1797 *
KROOK A ET AL: "RAPID AND SIMULTANEOUS DETECTION OF MULTIPLE MUTATIONS BY POOLED AND MULTIPLEX SINGLE NUCLEOTIDE PRIMER EXTENSION: APPLICATION TO THE STUDY OF INSULIN-RESPONSIVE GLUCOSE TRANSPORTER AND INSULIN RECEPTOR MUTATIONS IN NON-INSULIN-DEPENDENT DIABETES", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 1, no. 6, 1992, pages 391 - 395, XP000939000, ISSN: 0964-6906 *
NYHOLT D R ET AL: "FAMILIAL TYPICAL MIGRAINE LINKAGE TO CHROMOSOME 19P13 AND EVIDENCE FOR GENETIC HETEROGENEITY", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 50, no. 5, May 1998 (1998-05-01), pages 1428 - 1432, XP001053727, ISSN: 0028-3878 *
ODAWARA M ET AL: "HUMAN DIABETES ASSOCIATED WITH A MUTATION IN THE TYROSINE KINASE DOMAIN OF THE INSULIN RECEPTOR", SCIENCE (WASHINGTON D C), vol. 245, no. 4913, 1989, pages 66 - 68, XP001146085, ISSN: 0036-8075 *
SPLIT W ET AL: "HEADACHES IN NON INSULIN-DEPENDENT DIABETES MELLITUS", FUNCTIONAL NEUROLOGY, CIC EDIZIONI INTERNATIONALI, ROME, IT, vol. 12, no. 6, November 1997 (1997-11-01), pages 327 - 332, XP001028137, ISSN: 0393-5294 *
STEN-LINDER M ET AL: "DNA POLYMORPHISMS OF THE INSULIN-RECEPTOR GENE IN TYPE 2 DIABETES ASSOCIATION WITH FASTING BLOOD GLUCOSE", DIABETOLOGIA, vol. 33, no. SUPPL., 1990, pages A79, XP009006865, ISSN: 0012-186X *
T HART L M ET AL: "Association of the insulin-receptor variant Met-985 with hyperglycemia and non-insulin-dependent diabetes mellitus in the Netherlands: A population-based study.", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 59, no. 5, 1996, pages 1119 - 1125, XP009006921, ISSN: 0002-9297 *

Also Published As

Publication number Publication date
AU2001295752A1 (en) 2002-04-29
WO2002033121A2 (fr) 2002-04-25
GB0025678D0 (en) 2000-12-06

Similar Documents

Publication Publication Date Title
WO2001081919A3 (fr) Test de diagnostic de polypeptide inhibiteur gastrique destine a la detection de la sensibilite aux diabetes de type 2, a une intolerance au glucose, ou a une glycemie a jeun
WO2008055491A3 (fr) Diagnostic et stratification des risques de diabète sucré par mr-proadm
WO2002043758A3 (fr) Utilisation de genes et reactifs associes
WO2008038000A8 (fr) procédé de diagnostic pour détecter ou surveiller le cancer
WO2000040749A3 (fr) Technique de detection de transcrits geniques dans le sang et leur utilisation
TWI256975B (en) Compositions containing a urea derivative dye for detecting an analyte and methods for using the same
AU3725199A (en) 13c glucose breath test for the diagnosis of diabetic indications andmonitoring glycemic control
IL133611A0 (en) A method for preparing a substrate for detecting at least one analyte
DK0943097T3 (da) Fremgangsmåde til at påvise IgE
SE9601318D0 (sv) Method for nucleic acid analysis
WO2006127694A3 (fr) Detecteur d'analyte
WO2001061043A3 (fr) Genotypage parallele de plusieurs echantillons preleves sur des patients
EP1316802A3 (fr) Méthode d'analyse d'une reaction de la coagulation du sang
WO2003070894A3 (fr) Test diagnostique non invasif mettant en oeuvre des marqueurs de modification de l'histone
AU2001233785A1 (en) Electrochemical sensor for determining blood clotting, corresponding system for measuring blood clotting and method for determining blood clotting
WO2006026601A3 (fr) Dosage immunologique enzymatique homogene pour un fluide buccal
EP1234053A4 (fr) Appareil et procede pour faire des dosages de coagulation dans des echantillons liquides
CA2264939A1 (fr) Substances et methodes destinees au diagnostic et au traitement de la preeclampsie et du diabete
AU3772495A (en) Method for specifically detecting a coagulation factor V which has an increased stability toward activated protein C in the activated state
WO2003016906A1 (fr) Procede de diagnostic ou de controle d'une erreur du metabolisme du saccharose
WO1998014611A3 (fr) Detection et identification d'enterovirus non poliovirus
WO2005034737A3 (fr) Diagnostic et traitement de troubles du reticulum endoplasmique
WO2002035228A3 (fr) Procede et necessaire d'essai pour la detection d'analytes dans un echantillon
WO2000053625A3 (fr) Micro-reseaux de sondes d'affinite peptidique et techniques destines a l'analyse de produits geniques
WO2002033121A3 (fr) Test diagnostique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP